GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » Asset Turnover

Elevation Oncology (Elevation Oncology) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Elevation Oncology Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Elevation Oncology's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Elevation Oncology's Total Assets for the quarter that ended in Mar. 2024 was $99.03 Mil. Therefore, Elevation Oncology's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Elevation Oncology's annualized ROE % for the quarter that ended in Mar. 2024 was -65.57%. It is also linked to ROA % through Du Pont Formula. Elevation Oncology's annualized ROA % for the quarter that ended in Mar. 2024 was -43.25%.


Elevation Oncology Asset Turnover Historical Data

The historical data trend for Elevation Oncology's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elevation Oncology Asset Turnover Chart

Elevation Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - - -

Elevation Oncology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Elevation Oncology's Asset Turnover

For the Biotechnology subindustry, Elevation Oncology's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elevation Oncology's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elevation Oncology's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Elevation Oncology's Asset Turnover falls into.



Elevation Oncology Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Elevation Oncology's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (94.161+89.091)/ 2 )
=0/91.626
=0.00

Elevation Oncology's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (89.091+108.961)/ 2 )
=0/99.026
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Elevation Oncology  (NAS:ELEV) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Elevation Oncology's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-42.828/65.3135
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-42.828 / 0)*(0 / 99.026)*(99.026/ 65.3135)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.5162
=ROA %*Equity Multiplier
=-43.25 %*1.5162
=-65.57 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Elevation Oncology's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-42.828/99.026
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-42.828 / 0)*(0 / 99.026)
=Net Margin %*Asset Turnover
= %*0
=-43.25 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Elevation Oncology Asset Turnover Related Terms

Thank you for viewing the detailed overview of Elevation Oncology's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Elevation Oncology (Elevation Oncology) Business Description

Traded in Other Exchanges
N/A
Address
888 Seventh Avenue, 12th Floor, New York, NY, USA, 10106
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Executives
Tammy Furlong officer: CHIEF FINANCIAL OFFICER C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Goodman Corey S 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Robert J Adelman 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston 10 percent owner 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Valerie Malyvanh Jansen officer: Chief Medical Officer C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Andrew N Schiff other: Managing Member PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms director, other: Managing Member 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Vertex Global Hc Fund Ii Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
Walsh Colin director C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106